|
WO2017109204A1
|
|
Humanized mouse model of myasthenia gravis and msc therapy
|
|
WO2016016449A1
|
|
Treatment of amyotrophic lateral sclerosis
|
|
WO2015097259A1
|
|
Muscle-derived cell populations with cardiogenic differentiation capacities
|
|
WO2015158365A1
|
|
Treatment of myotonic dystrophy
|
|
CN104704123A
|
|
Widespread gene delivery of gene therapy vectors
|
|
FR2995522A1
|
|
DEVICE FOR MEASURING THE PINCH EFFORT BETWEEN INCH AND INDEX OF A PERSON
|
|
FR2988838A1
|
|
SYSTEM FOR MEASURING A PALMARY GRIP FORCE
|
|
FR2986959A1
|
|
DEVICE FOR EVALUATING THE DISTAL MOTRICITY OF THE UPPER MEMBERS OF AN INDIVIDUAL
|
|
EP2581448A1
|
|
Tricyclo-phosphorothioate DNA
|
|
EP2550021A2
|
|
Methods of increasing efficiency of vector penetration of target tissue
|
|
WO2011113889A1
|
|
Modified u7 snrnas for treatment of neuromuscular diseases
|
|
EP2500434A1
|
|
Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
|
|
EP2486136A1
|
|
Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
|
|
FR2961086A1
|
|
DEVICE FOR EVALUATING THE MOTOR CAPACITY OF THE UPPER MEMBERS OF AN INDIVIDUAL
|
|
CN102625840A
|
|
Tricyclo-DNA antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
EP2287323A1
|
|
Widespread gene delivery to the retina using systemic administration of AAV vectors
|
